TAK catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
December 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Dec 17, 2026Sponsor estimate | NCT07363720A Trial of TAK-861 for the Treatment of Narcolepsy With CataplexyTakeda · Narcolepsy Type 1 (NT1) | TAKLead | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
| Dec 31, 2026Sponsor estimate | NCT05013190A Study of NINLARO® in Chinese Adults With Multiple MyelomaTakeda · Multiple Myeloma | TAKLead | No phase registered | Active, not recruiting | Locked | Locked | Locked |
| Dec 31, 2026Sponsor estimate | NCT05469789A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)Takeda · Hereditary Angioedema (HAE) | TAKLead | No phase registered | Active, not recruiting | Locked | Locked | Locked |
| Dec 31, 2026Sponsor estimate | NCT07299097Epidemiology of Narcolepsy Type 1 and Type 2 in SpainTakeda · Narcolepsy Type 1 | TAKLead | No phase registered | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Dec 17, 2026Sponsor estimatePhase 3NCT07363720A Trial of TAK-861 for the Treatment of Narcolepsy With CataplexyTakeda · Narcolepsy Type 1 (NT1)Active, not recruitingTAKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT05013190A Study of NINLARO® in Chinese Adults With Multiple MyelomaTakeda · Multiple MyelomaActive, not recruitingTAKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT05469789A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)Takeda · Hereditary Angioedema (HAE)Active, not recruitingTAKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT07299097Epidemiology of Narcolepsy Type 1 and Type 2 in SpainTakeda · Narcolepsy Type 1Active, not recruitingTAKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 1, 2027Sponsor estimate | NCT04869280Post-Marketing Study of Prucalopride Safety In PregnancyTakeda · Chronic Idiopathic Constipation (CIC) | TAKLead | No phase registered | Active, not recruiting | Locked | Locked | Locked |
| Feb 5, 2027Sponsor estimate | NCT07244263A Study of Zasocitinib in Adults With Hidradenitis SuppurativaTakeda · Hidradenitis Suppurativa | TAKLead | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Feb 10, 2027Sponsor estimate | NCT06973304A Study of Teduglutide in Chinese Adults With Short Bowel SyndromeTakeda · Short Bowel Syndrome | TAKLead | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Feb 1, 2027Sponsor estimateNo phase registeredNCT04869280Post-Marketing Study of Prucalopride Safety In PregnancyTakeda · Chronic Idiopathic Constipation (CIC)Active, not recruitingTAKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 5, 2027Sponsor estimatePhase 2NCT07244263A Study of Zasocitinib in Adults With Hidradenitis SuppurativaTakeda · Hidradenitis SuppurativaActive, not recruitingTAKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 10, 2027Sponsor estimatePhase 3NCT06973304A Study of Teduglutide in Chinese Adults With Short Bowel SyndromeTakeda · Short Bowel SyndromeActive, not recruitingTAKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 7 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.